Transcript 2011 WP - EMCDDA

Overview of the 2011 Work Programme
Paul Griffiths
Scientific committee meeting, Lisbon, November 2010
Overview
2011 WP
Highlights
Core activities
Key indicators
Monitoring
responses
Transversal
analysis
• Three-year strategy (2010–2012) will be
implemented through 3 annual work
plans, 2011 WP is the 2’nd
• Heart of the agency work remains:
• State of the art review of the drug phenomenon
• Maintaining an up to date reference point on drugs
• Providing ongoing support to EU institution and
Member states for monitoring and implementing the
EU strategy and action plan
Supply
reduction
2
2011 focus
2011 WP
Highlights
Core activities
Key indicators
Monitoring
responses
Transversal
analysis
Supply
reduction
• Ensuring European system fits for the purpose
& remaining responsive to developments
• Further dissemination of best practice
• Developing information sources in supply
reduction
• Support the evaluation of the EU strategy and
action plan
• Focus on polydrug use, combined analysis,
policy-relevance analysis
• Dissemination and valorising EMCDDA
findings
3
State of the art review
2011 WP
Highlights
Core activities
Key indicators
Monitoring
responses
Transversal
analysis
Supply
reduction
• Preparation of the Annual report package
• Efficient and methodologically sound data
input, management and processing
• Top level strategic review of data
collected and appropriateness of the
instruments used
• Continue development of statistical
bulletin
• Further technical development of FONTE
and data warehouse
4
Remain methodologically sound
2011 WP
Highlights
Core activities
Key indicators
Monitoring
responses
Transversal
analysis
• Efficient collection and analysis of the KIs
• Maintaining and strengthen network
• Increase quality and comparability
•
•
•
•
•
•
Better integration of youth survey (GPS)
Final stage of rationalisation of TDI
Broadening scope of PDU
Update protocol of DRID
Improve tools for mortality cohort data collection
New data lab workshop (GPS, mortality registries)
Supply
reduction
5
2011 WP
Highlights
Core activities
Key indicators
Monitoring
responses
Transversal
analysis
Supply
reduction
Support to EC and rationalise data
collection
• Support to the Council recommendation
on prevention and reduction of health
related harm
• Investigate and develop models for
collecting data on:
• Opiates substitution treatment
• GPs
• Low-threshold agencies
• Cochrane systematic review on media
campaigns
• Conceptual framework for coherent set of
response indicators
6
Cross analysis and CUPs
2011 WP
Highlights
Core activities
•
•
•
•
Treatment coverage in subgroups of users
Alcohol cannabis connections
Polydrug use
Drugs and driving
Key indicators
Monitoring
responses
Transversal
analysis
Supply
reduction
• CUP treatment: coherent supportive and
scientifically sound approach for monitoring
treatment in Europe
• CUP prison: scale up monitoring of prison setting
• CUP modelling: identify and support policy relevant
analyses
7
2011 WP
Development and adoption of
indicators
Highlights
Core activities
Key indicators
Monitoring
responses
• Improving understanding of Europe’s
specialised police units
• 3 expert groups (drug markets, drugrelated crime, drug supply reduction)
• Second technical conference on DSSR
Transversal
analysis
Supply
reduction
8
Combine EWS and emerging trends
2011 WP
New drugs
Policy
Good
practice
Main outputs
•
•
•
•
•
Implement efficiently Council Decision (EWS)
Assist in assessment of the Council decision
Structured internet monitoring
Further develop links with forensic/toxicology
Trend-spotting- develop integrated approach for
monitoring emerging trends
• Initial implementation of monitoring of misuse of
medicinal products
• Multidisciplinary project on monitoring illicit drugs
in waste water
9
2011 WP
New drugs
Policy
Good
practice
Main outputs
Improving Europe’s capacity to
monitor and evaluate policies
• Review and develop framework for drug
policy analysis
• Study on drug policy advocacy groups
• Contribute to the evaluation of the EU
strategy and action plan
• And provide appropriate support to the
commission in this area
• Model the impact on unemployment on
drug issues
10
2011 WP
New drugs
Policy
Good
practice
Main outputs
Expend BPP and promote
cooperation with scientific community
• Support EU project on standard and
guidelines for interventions harm
reduction and social rehabilitation
• Expend and continue promoting best
practice in Europe
• Promote and facilitate EU research on
drug issues
• Net work with scientific community and
relevant organisations
11
2011 WP
New drugs
Policy
Good
practice
Main outputs
• Annual report
package
• EU drug strategy
• Scientific
• Annual report
Monograph
• Statistical bulletin
• Insights
• Manuals
• Selected issues (treatment
• Drug policy profiles
guidelines, cost of
• Drugs in Focus
treatment, mortality)
• Thematic papers
• Joint publications
• Online tools
• Articles
12
2011 WP
New drugs
Policy
Good
practice
Main outputs
• Annual report
package
• Situation and responses
• EU drug strategy
review since 2005
• Scientific
Monograph
• Insights
• Manuals
• Drug policy profiles
• Drugs in Focus
• EMCDDA public website
• Thematic papers
• Best practice portal
• Joint publications
• ELDD
• Online tools
• Articles
• Country intervention
profiles
13
2011 WP
New drugs
Policy
Good
practice
Main outputs
• Annual report
package
• EU drug strategy
• Scientific
• New groups of
Monograph
psychoactive substances
• Insights
• Manuals
• Drug policy profiles
• Drugs in Focus
• Thematic papers
• European ecstasy market
• Joint publications
(Europol)
• Online tools
• Guidance on prevention of
• Articles
infections among IDus
(ECDC
14
2011 WP
New drugs
Policy
Good
practice
Main outputs
• Annual report
package
• EU drug strategy
• Scientific
Monograph
• Insights
• Manuals
• Drug policy profiles
• Drugs in Focus
• Thematic papers
• Joint publications
• Online tools
• Articles
• Cannabis market and
production
• Heroin-assisted treatment
• Models of dependency and
compulsive behaviour
• Emerging drug trends case
study
• Drug couriers
• New methods for cross
analysis of prevention trials
• Drug user perspective in
quitting drug use, etc….
15
2011 WP
New drugs
Policy
Good
practice
Main outputs
• Annual report
package
• EU drug strategy
• Scientific
Monograph
• Insights
• Manuals
• Drug policy profiles
• Drugs in Focus
• Thematic papers
• Joint publications
• Online tools
• Articles
• DRID protocol
• Mortality cohort protocol
• Guidelines for evaluation
of national drug strategies
• Responding to
psychoactive substances
• Minimum quality standard
of interventions
• Drug-related research
• Khat
16
2011 WP
New drugs
Policy
Good
practice
Main outputs
• Annual report
package
• EU drug strategy
• Scientific
Monograph
• Insights
• Manuals
• Drug policy profiles
• Drugs in Focus
• Thematic papers
• Joint publications
• Online tools
• Articles
• New series of national
drug policy profiles
17
Questions and discussion